JCARH 125 - Juno Therapeutics

Drug Profile

JCARH 125 - Juno Therapeutics

Alternative Names: Anti-BCMA chimeric antigen receptor cell therapy - Juno Therapeutics; BCMA CAR T - Juno Therapeutics; BCMA Targeted CAR T Cells - Juno Therapeutics; BCMA-specific CAR T - Juno Therapeutics; BCMA-specific CAR-expressing T Lymphocytes - Juno Therapeutics; EGFRt/BCMA-41BBz CAR T cell; JCARH125

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Juno Therapeutics
  • Developer Juno Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines; CAR-T cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 06 Dec 2017 Juno Therapeutics and Eli Lilly agree to develop crenigacestat, in combination with BCMA-directed CAR T cell therapies, for Multiple myeloma
  • 06 Dec 2017 Juno Therapeutics in-licenses rights to intellectual property using gamma secretase inhibitors, in combination with BCMA-directed CAR T cell therapy from OncoTracker and Fred Hutchinson Cancer Research Center
  • 06 Dec 2017 Juno Therapeutics plans a clinical trial for Multiple myeloma (Combination therapy) in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top